首页> 外文OA文献 >A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13

【2h】

A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13

机译：将Pemetrexed Plus顺铂进行随机开放标签的II次研究，然后通过单独的表皮生长因子受体（EGFR） - 富富毒素激酶抑制剂失败后单独维持Pemetrexed与培养型培养型培养型培养基患者： KCSG-LU12-13

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Kwai Han Yoo; Su Jin Lee; Jinhyun Cho; Ki Hyeong Lee; Keon Uk Park; Ki Hwan Kim; Eun Kyung Cho; Yoon Hee Choi; Hye Ryun Kim; Hoon-Gu Kim; Heui June Ahn; Ha Yeon Lee; Hwan Jung Yun; Jin-Hyoung Kang; Jaeheon Jeong; Moon Young Choi; Sin-Ho Jung; Jong-Mu Sun; Se-Hoon Lee; Jin Seok Ahn; Keunchil Park; Myung-Ju Ahn;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study [J] . Shi Y. K., Wang L., Han B. H., Annals of oncology: official journal of the European Society for Medical Oncology . 2017,第10期

机译：第一线Icotinib对顺铂/磷磷酸蛋白/培养基加上晚期EGFR突变阳性肺腺癌（说服）的患者（说服）的患者的培养维性疗法：一个第3阶段，开放标签，随机研究
2. The PARAMOUNT trial: A phase III randomized study of maintenance pemetrexed versus placebo immediately following induction first-line treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer [J] . GridelliC., MaioneP., RossiA. Reviews on recent clinical trials . 2013,第1期

机译：PARAMOUNT试验：培美曲塞联合顺铂诱导一线治疗晚期非鳞状非小细胞肺癌后立即进行培美曲塞和安慰剂维持治疗的III期随机研究
3. PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed plus Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel plus Carboplatin plus Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non-Small-Cell Lung Cancer [J] . Zinner Ralph G., Obasaju Coleman K., Spigel David R., Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2015,第1期

机译：释放：随机，开放标签，第一线Pemetrexed Plus Carboplatin的第三阶段研究，然后进行维持培养型Pemetrexed与PACLitaxel Plus Carboplatin Plus Bevacizumab，然后在患者中进行维护贝伐单抗，患者患者先进的非小细胞肺癌
4. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. A Randomized Open-Label Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13 [O] . Kwai Han Yoo, Su Jin Lee, Jinhyun Cho, 2019

机译：一线EGFR酪氨酸激酶抑制剂失效后表皮生长因子受体（EGFR）-突变型非小细胞肺癌患者的培美曲塞加顺铂与培美曲塞单用与单独培美曲塞比较的随机开放标签II期研究： KCSG-LU12-13
7. 1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC) [O] . L. Paz-Ares, M.A. Socinski, J. Shahidi, 2016

机译：1320_pr：表皮生长因子受体（EGFR）患者的亚群分析 - 表达肿瘤患者：一种随机，多中心，开放标签，吉西拜齐铂（GC）加上Necitumumab（N）对GC的第一个研究阶段鳞状非小细胞肺癌（SQ-NSCLC）的患者（PTS）治疗患者（PTS）治疗

A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13

著录项

相似文献

相关主题

期刊订阅